
BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.
• VERA is facing resistance from sellers. Track the action here.

BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.
• VERA is facing resistance from sellers. Track the action here.